Further studies are warranted to validate these in a larger patient cohort and identify further markers of interest such as ROS1 and RET rearrangements, other EGFR mutants and in NRAS-, KRAS-mutated adenocarcinomas. This evidence concerns the gene KRAS and adenocarcinoma.